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sible, country profiles where BIOSIM-EPO have taken market shares. Methods: 
Countries inclusion criteria: legal definition and regulatory framework for biosimi-
lars close to the EU ones; at least 3 years of experience with BIOSIM-EPO in 2012; 
national biological market value higher than US$ 2.5 billion. Factors evaluated: 
national EPO market sizes, EPO retail/hospital distribution mixes, existence of policy 
incentives that promote BIOSIM-EPO prescriptions or substitution and BIOSIM-EPO 
prices relative to reference EPO. Data on medicine volumes, values and ex-manu-
facturer prices for all EPOs (alfa, BIOSIM-EPO (EPO alfa biosimilar), beta and second-
generation ones) were provided by IMS Health. Volumes were calculated in DDD 
(Defined Daily Doses) and prices in euros per DDD. Data were available from 2007 
until 2012. Results: EU-5 and Japan have been included. Germany: small-sized 
market, dominant retail market distribution, incentives to prescribe BIOSIM-EPO 
(quotas) and to substitute patented for ‘bioidenticals’ EPO, high BIOSIM-EPO uptakes 
(30.4% in 2012). Spain and Italy: medium-sized markets, dominant hospital distri-
bution, no incentives, 11.5% and 8.6% BIOSIM-EPO uptakes respectively. Japan: the 
largest market, mixed distribution channels, no incentives, 6.8% BIOSIM-EPO uptake. 
France: large-sized market, dominant retail market distribution, no incentives, 5.8% 
BIOSIM-EPO uptake. The UK: the smallest market, mixed distribution channels, no 
incentives, 2.0% BIOSIM-EPO uptake. The price differences between BIOSIM-EPO 
and their reference play no role at a global level (e.g. -10.8% in Germany and -26.9% 
in Japan). ConClusions: This study proved that EPO markets are highly country 
specific. There is no single specific profile for countries in which BIOSIM-EPO have 
significantly penetrated the market. Providing national prescription and substitu-
tion incentives is the only determining factor for BIOSIM-EPO uptakes. National EPO 
market sizes, EPO retail/hospital distribution mixes and BIOSIM-EPO prices relative 
to reference EPO are not significant factors.
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objeCtives: With a total volume of € 24 billion a year, Japan is the world’s second 
largest medical device market behind the US. It imports about 35% of the medical 
devices from abroad. Although imports have been increasing steadily over the 
past years, Japan still struggles to have similar access to advanced medical 
devices as the US and Europe. This research aimed to have a closer look at the 
Japanese medical device market, and further explore access barriers. Methods: 
This research was conducted through in-depth secondary research and inter-
views with a variety of stakeholders including payers, academics, and KOLs in 
Japan. Results: Unlike most markets where an FDA or CE mark is sufficient, 
medical devices in Japan require a separate in-country regulatory approval before 
reimbursement. Not only is this process long (approximately 2.2 years) but the 
requirements are much more stringent compared to the US or EU, often requiring 
local clinical data. This has resulted in many large med-tech companies staying 
away from the Japanese market. ConClusions: It is important for foreign manu-
facturers to understand the implications of the Japanese regulatory barriers and 
address them in their foreign market strategies allowing them to assess product 
viability early on.
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objeCtives: Concerns due to external reference pricing (ERP) have been expressed 
by industry regarding spill-over effects. It is also often argued that ERP can lead 
to a downward price convergence. The objective of this project was to gain bet-
ter understanding of price dynamics of ERP-based systems using a simulation 
model. Methods: A simulation model (developed for the EU Commission) was 
built to simulate the impact of ERP as main criterion to set drug price across 
28 European Union Member States, Iceland, Norway and Switzerland. Base case 
scenario simulated ERP price for a fictitious drug based on real ERP characteris-
tics. Twenty fictitious scenarios simulated ERP price when introducing changes 
in ERP characteristics and/or exogenous effects such as genericisation, changes 
in exchange rates, price cuts. These scenarios were chosen based on the potential 
rapid and important price erosion attributed to ERP. Impacts of these scenarios 
were classified depending on changes in average drug price versus the base 
case. Results: Applying solely ERP led to a low average drug price decrease (about 
15% at 10 years), with an apparent equilibrium reached in approximately 7-8 years. 
Price differentials between countries remained substantial over 10 years (about 
30%), suggesting a limited impact of ERP in price convergence. Even if impact 
differed depending on scenarios, all tested scenarios induced price decreases 
and demonstrated the spill-over effects of ERP. Frequent price revisions, itera-
tive price cuts, large country baskets, price calculation methods, genericisation 
impact and prices’ sources were among the most influent parameters on the 
evolution of the drug price over time through ERP-based systems. The repetition 
and combination of various policies generated average price decrease of 92% at 
10 years. ConClusions: This study is the first that quantifies the impact of vari-
ous ERP policies on price erosion. This is a useful tool to support policy decision 
making.
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objeCtives: Cost-utility analysis (CUA) provides valuable information on the 
value of medical technology and is used by many payers to inform coverage and 
the submissions that failed to demonstrate efficacy (52%). Characteristics associ-
ated with a PFR were being a biologic product, having an appropriate comparator, 
showing sufficient clinical evidence and being priced at a similar/lower price than 
the comparator. ConClusions: The presence of patient input was not associated 
with a PFR. The lack of significant association could be attributed to external fac-
tors that are not captured in CADTH’s summary reports and the limited sample 
size of data available. It remains unclear how patient input is integrated into the 
decision making process.
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objeCtives: This study aims to propose a new geographic administrative organi-
zation of Colombian municipalities for health care management purposes. Rather 
than responding to arbitrary political boundaries, this division should answer to 
health needs and capacities, in order to facilitate the development of targeted poli-
cies to reach universal coverage and improve access to health services. Methods: 
To achieve this, a big database was created: it contains information about different 
health-affecting topics: economic development, socio-cultural background, public 
and transportation services, environmental conditions and health indicators, sup-
ply and demand. These topics were measured with over 70 variables. After that, 
using a principal-component analysis, one or two indicators were created per topic. 
These indicators were used to build clusters that latter allowed the development of 
sanitary regions. Afterwards, another study was made in which people were tracked 
from their residence to the places where they received health services. Then, the 
country was divided into regions reflecting those migration flows. Finally, the study 
mingles both information -the clusters and migration networks- to determine a 
sanitary geography of Colombia. Results: Using the methodology, this study pro-
poses six clustering methodologies that are statistically significant and consistent 
with the reality of Colombia. Also, many networks were proposed, but 5 of them 
represented the national situation closely. Combining these alternatives, the study 
achieves its goal and creates a satisfactory segmentation of the country that is valu-
able for public policy. ConClusions: The proposed categories serve well the needs 
that originated this study and are an appropriate framework for health care manage-
ment purposes. In fact, the Colombian Ministry of Health has used it as an input for 
telemedicine and first infancy projects and health care reform. Its main conclusion 
is that health cannot be worked using political divisions. It is fundamental to use 
supply, demand and context criteria to determine regions useful for policymakers.
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objeCtives: To understand key stakeholder recommendations for the Centers 
for Medicare & Medicaid Services (CMS) regarding the application of its CED pol-
icy, the outcome of national coverage determinations (NCD) in which Medicare 
makes coverage contingent on additional evidence collection through a registry 
or prospective trials, and identify primary concerns with the policy across various 
stakeholders. Methods: The authors analyzed stakeholder comments submit-
ted to CMS during a public comment period on draft updates to the agency’s 2006 
CED policy. The comment period was from November 29, 2012 to January 28, 2013. 
Comments were retrieved from CMS’ Medicare Coverage Database and assessed to 
understand stakeholder positions on issues related to the CED process. Results: 
Of the 27 stakeholders who submitted comments to CMS, over half were from the 
life sciences industry. The majority of stakeholders called for CMS to provide more 
clarity on how the agency plans to address operational issues with CED imple-
mentation. Stakeholders who may be impacted by the issuance of a CED, such as 
manufacturers, are seeking greater transparency from CMS on policies and pro-
cesses for applying CED as well as greater clarity on the parameters for executing 
CED studies. Specifically, 17 stakeholders called on CMS to prohibit CED at the local 
level and restrict its application to the NCD process while 12 stakeholders recom-
mended CMS to provide clear timelines for the duration of CED studies. In addition, 
11 stakeholders requested clarity from CMS on how it intends to collaborate with 
the Food and Drug Administration (FDA) on post-market evidence requirements, 
urging that CED should not duplicate or replace FDA’s authority. ConClusions: 
Going forward, CMS will likely continue to invoke CED with increasing frequency 
and potentially on a broader range of products. Therefore, clearer guidance from 
CMS is critical to ensuring continued stakeholder engagement through Medicare’s 
coverage determination process.
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objeCtives: Analyze factors influencing Erythropoietins (EPO) biosimilars (cop-
ies of patented EPO) (BIOSIM-EPO) uptakes in key global markets. Identify, if pos-
